Collectively, Tmunity’s scientific founders have more than 20 years of experience in HIV clinical studies, including adoptive transfer of retroviral-modified CD4-CD3 CAR-T cells and first-in-human studies of lentiviral vectors and zinc finger nucleases.
Tmunity is leveraging this expertise to apply multiple strategies to the creation of HIV-specific and HIV-resistant T cells that could make the immune system “HIV-proof” by making it impossible for HIV to escape. These approaches include:
Repopulating T cell compartments with HIV-resistant and HIV-specific immunity
Targeting HIV [Env] with genetically modified autologous T cells expressing optimized CD4-CAR
Protecting T cells from HIV infection by disrupting CCR5 or CXCR4 co-receptor expression
Activating HIV-1 reservoir with a latency reversal agent and measuring durable impact of engineered T cells
Tmunity is planning to initiate Phase 1 clinical studies in HIV in Q1 2018.